Skip to content

Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins

The FEASST Study: Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05368194
Acronym
FEASST
Enrollment
43
Registered
2022-05-10
Start date
2021-10-20
Completion date
2022-07-01
Last updated
2023-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epigenetic Disorder, Fertility Issues, Nutrition, Healthy, Overnutrition

Brief summary

The purpose of this study is to elucidate the role of acute dietary intake in male populations, and its impact on spermatozoa quality, integrity, content and epigenetic programming.

Detailed description

The FEASST study has been designed to determine the impact of diet on the content, quality, and genetic programming of sperm. They are specifically interested in determining if a man's diet plays a role in influencing the health of his potential, future offspring through modifications of the sperm. Previous research has highlighted that certain dietary patterns in fathers-to-be may lead to variable health outcome for their children. However, the specific effect of a man's diet has yet to be fully understood. This study will help understand the impact of a man's diet on semen quality and potential downstream implications for child health, to aid in the development of dietary guidelines for future fathers-to-be. For this study, male participants will be provided with two prescribed diets for three-week increments punctuated by a three month break. Health information and biological samples such as blood, semen, and saliva will be collected from study participants throughout the five month period. The diets will consist of a 'Processed diet', mimicking a traditional Western dietary intake pattern and an 'Unprocessed diet', based upon current dietary guidelines at quantities either adequate for the participants energetic needs or 500 calories in excess per day. Patient information and samples will be collected before and after each dietary intervention. Aspects of patient health examined at various time points include weight, body fat percentage, sperm quality, epigenetic sequencing, serum levels of metabolic parameters, and survey information surrounding health history, typical diet, physical activity patterns, and treatment adherence.

Interventions

DIETARY_SUPPLEMENTIsocaloric Unprocessed Diet

Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.

DIETARY_SUPPLEMENTIsocaloric Processed Diet

Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.

DIETARY_SUPPLEMENTExcess Calorie Unprocessed Diet

Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.

DIETARY_SUPPLEMENTExcess Calorie Processed Diet

Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.

Sponsors

Deakin University
CollaboratorOTHER
Monash Health
CollaboratorOTHER
University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Male * 20 to 35 years old * BMI 18.5 to 30 * Located within the Copenhagen region * Fluent in English and/or Danish language * Sperm concentration of \>15 mil/mL according to the WHO's criteria for semen quality * Semen volume of \>1.5mL mL according to the WHO's criteria for semen quality * Clinician approval for participation in study * Obtained informed consent

Exclusion criteria

* Self-reported history of serious or chronic illness * Self-reported history of Obesity * History of any food restrictions * History of allergies to any food products * History of disordered eating * Record of current use of drugs, alcohol (\>14 units per week and/or chronic binge drinking), and/or tobacco/nicotine products within the past month * Current use of prescription medication * Engage in \> 200 minutes of vigorous aerobic exercise per week * Currently actively trying to conceive a child * Diagnosis of infertility or disease of the reproductive system * Evidence of dysregulated metabolism, characterized by the occurrence of any one of the following: * Waist circumference \>102 cm * Blood pressure \> 130/85 mm Hg

Design outcomes

Primary

MeasureTime frameDescription
Spermatozoa DNA Methylation via Reduced Representation Bisulfite Sequencing3 weeksDifferential methylation of CpG sites within mature spermatozoa determined from extracted genomic DNA which has undergone library preperation with Ovation® RRBS Methyl-Seq (NuGEN Technologies) and sequenced on a NextSeq Illumina platform.

Secondary

MeasureTime frameDescription
Semen Volume3 weeksMeasured in mL assuming the density of semen to be 1 g/ml
Sperm Motility3 weeksMeasured in precent of sperm classified as progressively motile and non-progressively motile using LensHooke X1 Pro Semen Quality Analyser and Microscopy-based methodology
Spermatozoa smallRNA expression via sequencing of total smallRNA species3 weeksDifferential expression of small RNA species within mature spermatozoa performed by generation of RNA sequencing libraries using NEXTFLEX® Small RNA-Seq Kit for Illumina (PerkinElmer), according to the manufacturer's instructions, and sequenced on a NextSeq Illumina platform.
Weight3 weeksMeasured in kilograms using a scale (Tanita DC 430 SMA)
Body Mass Index (BMI)3 weeksCalculated based on height and weight measurement using the equation BMI=kg/m\^2
Waist Circumference3 weeksMeasured in centimetres using a flexible measuring tape (SECA Measuring Tape 201 cm)
Hip Circumference3 weeksMeasured in centimetres using a flexible measuring tape (SECA Measuring Tape 201 cm)
Body Fat Precentage3 weeksMeasured using DEXA Scanner and Software (GE Lunar Prodigy)
C-reactive protein (CRP)3 weeksMeasured in milligrams per litre in serum
Lipoproteins3 weeksMeasuring high density lipoproteins and low density lipoproteins in milligrams per litre in plasma
Total protein3 weeksMeasured in grams per litre in serum
Testosterone3 weeksMeasured in nanograms per deciliter in plasma
Follicle stimulating hormone (FSH)3 weeksMeasured in international units per milliliter in serum
Luteinizing hormone (LH)3 weeksMeasured in international units per liters in plasma
Sperm Concentration3 weeksMeasured in million sperm per mL using LensHooke X1 Pro Semen Quality Analyser and Microscopy-based methodology
Estradiol3 weeksMeasured in picograms per milliliter in serum
Oestradiol3 weeksMeasured in picograms per milliliter in serum
Fasting Blood Glucose3 weeksMeasured in whole blood using a handheld glucometer and test strip (Contour next Blood Glucose Meter and Blood Sugar Test strip)
Insulin3 weeksMeasured in microunits per milliliter in serum
Haemoglobin A1c (HbA1c)3 weeksMeasured in mmol/mol in plasma
Blood pressure3 weeksSystolic and Diastolic blood pressure measured in mmHg using an automatic blood pressure cuff (Omron M6 Comfort Automatic Upper Arm Blood Pressure Monitor, 22-42cm)
Leptin3 weeksMeasured in ng/mL in plasma
Glucagon-like peptide 1 (GLP-1)3 weeksMeasured in pmol/L in plasma
Gastric inhibitory peptide (GIP)3 weeksMeasured in pg/mL in serum
Glucagon3 weeksMeasured in pg/mL in serum
Ghrelin3 weeksMeasured in pg/mL in plasma
Fibroblast growth factor 21 (FGF-21)3 weeksMeasured in pg/ml in serum
Peripheral blood mononuclear cell (PBMC) DNA methylation via Reduced Representation Bisulfite Sequencing3 weeksDifferential methylation of CpG sites within PBMCs determined from extracted genomic DNA which has undergone library preperation with Ovation® RRBS Methyl-Seq (NuGEN Technologies) and sequenced on a NextSeq Illumina platform.
Progesterone3 weeksMeasured in nanograms per milliliter in serum

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026